Monday, February 22, 2016

National Adult Immunization Plan Establishes Key Goals Through 2020


In this Issue

•  IVIG/Albumin Supply Index
•  Open Market Pricing
•  New Products from FFF
•  Current Medicare
•  Resources
•  Subscribe to IG Living and BioSupply Trends Quarterly

The National Vaccine Program Office has published the National Adult Immunization Plan that provides an overview of actions needed by federal and nonfederal partners to protect public health and achieve optimal prevention of infectious diseases and their consequences through vaccination of adults. [ read more ]

New Type of Sound Wave May Allow for Inhalable Vaccines

A new form of hybridized sound waves developed by Australian researchers may allow drugs and vaccines to be delivered to the body through a nebulizer in a fine mist that is inhaled into the lungs. [ read more ]

IVIG May Ameliorate Gastrointestinal Complications in Systemic Sclerosis

Significant improvements in the Gastrointestinal Tract (GIT) 2.0 score, skin score and other sequelae of system sclerosis were observed by United Kingdom investigators in an observational study of high-dose intravenous immune globulin (IVIG).
[ read more ]

Industry News


From Octapharma

Octapharma USA announced that NUWIQ antihemophilic factor (recombinant) is now commercially available. NUWIQ is indicated for
the treatment and control of bleeding,
perioperative (surgical) management and routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia A. [ read more ]

From Grifols

Grifols has reached an agreement with MassBiologics (MBL) of the University of Massachusetts Medical School that gives Grifols exclusive rights to market and distribute MBL’s tetanus and diphtheria toxoids adsorbed vaccine in the United States with the exception of Massachusetts, where MBL will continue distributing the vaccine.
[ read more ]

From ADMA Biologics

New Jersey-based ADMA Biologics announced that it has expanded its commercial operations team in anticipation of the approval of its investigational human plasma-derived intravenous immunoglobulin product (RI-002), intended for the treatment of primary immune deficiency disease. [ read more ]

IVIG & Albumin Supply Index


Featured Product Of The Month

Bivigam (Kedrion Biopharma)

BIVIGAM (immune globulin intravenous (human) 10% liquid) is indicated for the treatment of primary humoral immunodeficiency, including but not limited to the humoral immune defect in common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiencies. The product has a median half-life of 30 days, contains no sucrose/glucose/maltose, is stabilized with glycine, has trace amounts of IgA, contains a latex-free stopper, features tamper-evident seals and can be stored for up to 24 months (until expiration date on vial packaging) at 2 degrees to 8 degrees Centigrade.

For more information about Bivigam, go to

Nuwiq (Octapharma)

NUWIQ is a recombinant antihemophilic coagulation Factor VIII indicated in adults and children with Hemophilia A for: 1) on-demand treatment and control of bleeding episodes; 2) perioperative management of bleeding; and 3) routine prophylaxis to reduce the frequency of bleeding episodes. Nuwiq is not indicated for the treatment of von Willebrand Disease. It is available in four vial sizes: 250 IU, 500 IU, 1000 IU and 2000 IU. Store at 2 – 8°C (35 – 46°F) for up to 24 months. Do not freeze.

Miacalcin (Mylan Institutional)

MIACALCIN (calcitonin-salmon) synthetic injection is for subcutaneous or intramuscular use and is indicated for the following conditions: 1) hypercalcemia; 2) Paget’s disease of bone; and 3) postmenopausal osteoporosis. It is available as a sterile solution in individual 2 mL multi-dose vials containing 200 IU per mL, and should be refrigerated between 2 degrees to 8 degrees Centigrade.

Zarxio (Sandoz Inc.)

ZARXIO (filgrastim-sndz) injection is for subcutaneous or intravenous use. It is a leukocyte growth factor indicated for: 1) patients with cancer receiving myelosuppressive chemotherapy; 2) patients with acute myeloid leukemia receiving induction or consolidation chemotherapy; 3) patients with cancer undergoing bone marrow transplantation; 4) patients undergoing autologous peripheral blood progenitor cell collection and therapy; and 5) patients with severe chronic neutropenia. This product must be stored in a refrigerator at 2 degrees to 8 degrees Centigrade in the original pack to protect from light. Do not shake, do not freeze. Prior to injection, the product may be allowed to reach room temperature for a maximum of 24 hours.

Imovax Rabies (Sanofi Pasteur)

IMOVAX Rabies is a vaccine indicated for pre-exposure and post-exposure prophylaxis against rabies and is approved for use in all age groups. The freeze-dried vaccine is stable if stored in the refrigerator between 2 degrees to 8 degrees Centigrade. Do not freeze. The product is a sterile, stable, freeze-dried suspension of rabies virus prepared from strain PM-1503-3M obtained from the Wistar Institute, Philadelphia, PA.

These products can be ordered from FFF Enterprise's BioSupply Online Ordering System or by calling Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective January 1, 2016, through March 31, 2016.

Product J Codes ASP + 6%
(before sequester)
ASP + 4.3%*
(after sequester)
Bivigam J1556 $77.72 $76.47
Carimune NF J1566 $69.79 $68.67
Flebogamma J1572 $78.72 $77.46
Gammagard S/D J1566 $69.79 $68.67
Gammaplex J1557 $74.62 $73.43
Octagam J1568 $84.88 $83.52
Privigen J1459 $76.51 $75.28
Hizentra J1559 $84.69 $83.33
HyQvia J1575 $108.30 $106.56
Gammagard Liquid J1569 $76.23 $75.01
Gammaked J1561 $83.53 $82.19
Gamunex-C J1561 $83.53 $82.19

*Reflects 2% sequestration reduction applied to 80% Medicare payment portion as required under Budget Control Act of 2011.


FFF customers may order the following complementary resources to help you with your practice:

•  IG Immune Globulin (Human)
•  Hyperimmune Globulins
•  Anti-Inhibitor, Factor VIIa & IX
•  Factor VIII & von Willebrand Factor
•  Seasonal Influenza Vaccine

Subscribe to IG Living

IG Living is the only magazine for the immune globulin (IG) community for patients who suffer from chronic illness and their caregivers.

Subscribe to BioSupply
Trends Quarterly

BioSupply Trends Quarterly magazine is the definitive source for industry trends, news and information for the biopharmaceuticals marketplace.

Home | About | Advertise | Subscribe | Contact – ©2016 FFF Enterprises, Inc.